探索外国成本效益分析对西班牙的概括性,使用跨国研究范围审查的数据
Lidia García-Pérez1,2,3, Ignacio Abásolo-Alessón4, Miguel Ángel Negrín-Hernández5
1Servicio de Evaluación del Servicio Canario de la Salud (SESCS), El Rosario, Spain. lidia.garciaperez@sescs.es.
PharmacoEconomics
|September 25, 2025
概括
外国经济评估,特别是来自欧元区国家和英国的毒品,往往可以将其推广到西班牙. 然而,当可行时,国家特定的研究仍然是有价值的,特别是在其他健康技术方面.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 卫生技术评估 卫生技术评估
背景情况:
- 经济评估对于医疗保健决策至关重要.
- 外国经济评估对西班牙医疗保健系统的概括性需要审查.
- 成本效益分析 (CUA) 经常用于医疗技术评估.
研究的目的:
- 描述跨国CUAs中的跨国适应方法.
- 评估西班牙和外国结果之间一致的融资决策的概率.
- 确定影响经济评估对西班牙的概括性的因素.
主要方法:
- 对包括西班牙在内的跨国CUAs进行了范围审查.
- 提取和合成了关于可转移性的数据.
- 一个多层逻辑模型分析了基于增量成本效益比率 (ICER) 和增量质量调整寿命年 (QALY) 的决策一致性.
主要成果:
- 包括57项研究,主要是行业资助和欧洲研究.
- 84%的外国结果与西班牙成本效益平面象限相匹配.
- 93%的资助决定是一致的,假设€30,000/QALY值.
- 对于欧元区国家和英国的研究,一致性增加.
结论:
- 来自欧元区国家和英国的外国CUAs为西班牙的决策提供了宝贵的见解.
- 如果可行,仍应优先考虑针对特定国家的研究.
- 对其他健康技术和解决研究局限性的进一步研究是必要的.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
375
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
375
Bioequivalence Data: Statistical Interpretation
178
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
178
Bioequivalence of Drugs: Drugs with Multiple Indications
134
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
134
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
150
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
150
Analysis of Population Pharmacokinetic Data
643
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
643
Bias in Epidemiological Studies
1.2K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
1.2K


